

EMVision Medical Devices Ltd
ACN 620 388 230
Level 10, 12 Creek Street,
Brisbane Qld 4000
02 8667 5337
contact@emvision.com.au

ASX Release

EMVISION'S 1st GEN PORTABLE BRAIN SCANNER READY FOR TESTING FOLLOWING SUCCESSFUL MANUFACTURE

EMVision Medical Devices Limited (ASX:EMV) ("EMVision" or the "Company"), a medical device company focused on the development and commercialisation of portable medical imaging technology, is pleased to announce that fabrication and assembly of the Company's alpha unit of its 1st Gen portable brain scanner intended for commercialisation, has been completed.

"This is an important milestone for the Company. Our product represents a game changing opportunity to provide accessible point-of-care neuroimaging for stroke patients, wherever they are. The value proposition for our scanner is simple – portable, accessible, fast, safe and affordable. We are tackling the immense health burden that is stroke, with potential future adjacencies in traumatic brain injury and other neurological disorders. We see an enormous market opportunity ahead in neuroimaging that is poised for disruption. Our device will undergo various tests as we prepare for our next stage of expanded clinical studies." said EMVision CEO Dr Ron Weinberger.



EMVision CEO Dr Ron Weinberger pictured alongside the 1st Gen unit (L) and earlier Clinical Prototype (R)

The 1st Gen units will be the subject of functional, reliability, integration (software and hardware), preliminary safety, performance, compliance and other tests intended to meet international regulatory standards in preparation for expanded clinical studies. Product suitability for manufacturability, assembly, shipment (environmental impact), use, service and repair will also be assessed.



EMVision's portable brain scanner device is designed for use in hospitals, clinics, and other settings where conventional neuroimaging machines are not accessible or practical.

Co-chairs of the Australian Stroke Alliance and past presidents of the World Stroke Organisation, Professors Stephen Davis AO and Geoffrey Donnan AO welcomed the progress. Geoffrey Donnan: "The Australian Stroke Alliance's research revolves around the successful design of light and portable scanning equipment so we can speed-up diagnosis and treatment of patients. We look forward to collaborating with EMVision as it enters the next phase of clinical studies using this cart-based device."

Stephen Davis: "It is encouraging to see the progress being made because portable scanning that provides high quality brain imaging would be indispensable, particularly for the one third of Australians who live in rural and remote communities and might suffer a stroke. If the research program is successful, these scanners could also be incorporated into standard ambulances and aircraft."

Authorised for release by the Board of the Company.

[ENDS]

For further information, media or investor enquiries, please contact:

Andrew Keys
Investor Relations
+61 400 400 800
andrew.keys@keysthomas.com

Sling & Stone
Media and Communications
emvision@slingstone.com
02 8073 5390

Scott Kirkland
Executive Director
+61 2 8667 5337
skirkland@emvision.com.au

About EMVision Medical Devices

EMVision Medical Devices Limited is focused on the development and commercialisation of medical imaging technology. The Company is developing and seeking to commercialise a potentially cost effective, portable, medical imaging device using electromagnetic microwave imaging for diagnosis and monitoring of stroke and other medical applications. The technology is the result of over 10 years of development by researchers at the University of Queensland. The team of approximately 20 researchers is led by co-inventor Professor Amin Abbosh, who is considered a global leader in electromagnetic microwave imaging. EMVision's Chief Scientific Officer is Professor Stuart Crozier, who is a co-inventor and is globally renowned for creating technology central to most MRI machines manufactured since 1997. EMVision's CEO, Dr Ron Weinberger, is the Former Executive Director and CEO of Nanosonics' (ASX:NAN), a \$1.6 billion market cap healthcare company. Dr Weinberger has over 25-years' experience developing and commercialising medical devices. During his time at Nanosonics, Dr Weinberger co-developed the company's platform technology and launched their breakthrough product 'Trophon' globally, which would go on to become the gold standard for infection prevention. Dr Weinberger was instrumental in transforming Nanosonics from a research and development company to one of Australia's leading medical device commercialisation success stories.

Forward-looking Statements

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of EMVision and certain of the plans and objectives of EMVision with respect to these items. These forward-looking statements are not historical facts but rather are based on EMVision's current expectations, estimates and projections about the industry in which EMVision operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of EMVision, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. EMVision cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of EMVision only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. EMVision will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.